Immunic Phase 2 EMPhASIS trial data highlighted in peer-reviewed neurology journal
Immunic Inc CEO Dr Daniel Vitt joined Proactive's Stephen Gunnion with news of the publication of extended data from the Phase 2 EMPhASIS trial of vidofludimus calcium in relapsing-remitting...